Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. CGEN
CGEN logo

CGEN News & Events

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

CGEN News

Compugen Reports Q1 2026 Financial Results and Corporate Update

May 18 2026PRnewswire

Compugen Q1 Earnings: Revenue Beats Expectations

May 18 2026seekingalpha

Compugen Scheduled to Announce Q1 Earnings on May 18

May 17 2026seekingalpha

Compugen to Present at 2026 Stifel Virtual Oncology Forum

May 12 2026PRnewswire

Compugen to Release Q1 2026 Financial Results on May 18

May 04 2026PRnewswire

Compugen to Present at 25th Annual Needham Virtual Healthcare Conference

Apr 09 2026PRnewswire

Compugen Reports 2025 Financial Results and Strategic Update

Mar 02 2026PRnewswire

Compugen Q4 Earnings Exceed Expectations with Significant Revenue Growth

Mar 02 2026seekingalpha

CGEN Events

05/18 19:00
US Treasury Yields Rise, Market Sentiment Weighed Down
With earnings season mostly in the rearview mirror outside of Nvidia'sQ1 results this week, the macro component has returned to dominate the market narrative, and the global "rate shock" is clearly weighing on sentiment.  US 10-year Treasury Note yield closed above 4.6% for the first time since early 2025 and the 30-year reached 5.15% - both up by over 50 basis points from late February just before the start of the Iran war - as markets continue to fret over stagflation backdrop, sending major indices in the red for much of the day.Similar to Friday, Monday's notable rotation away from the AI disruption trade continued as Semiconductors were largely lower while Software names saw some notable dip-buying.  Names like Cognizant, ServiceNow, and EPAM Systemswere among the leaders in the S&P 500. In turn, the AI infrastructure buildout "winners" like Micronand Sandiskwere among the 10 weakest stocks in the benchmark.In the opening hour of the evening session, U.S. equity futures are modestly higher, with traders responding to the latest Truth Social post from President Trump announcing a delay to resumption of strikes by US military on Iranian infrastructure with hopes for a deal that addresses Tehran's nuclear ambitions.  S&P e-minis and Nasdaq 100 contracts are up about 0.2% while July WTI Crude Oil is down 2% below $102.50 per barrel.Check out this evening's top movers from around Wall Street, compiled by The Fly.HIGHER AFTER EARNINGS -Agilysysup 13.6%ALSO HIGHER -Penguin Solutionsup 3.5% after naming David Heard, President of Network Infrastructure at Nokia, to BoardNomad Foodsup 1.6% after insider buyDOWN AFTER EARNINGS -XP Inc.down 5.1%Bally's Corporationdown 2.5%Yalla Groupdown 2.5%ALSO LOWER -Compugendown 3.5% after equity offering
05/18 16:10
Compugen Files $400M Mixed Securities Shelf
Compugen files $400M mixed securities shelf
05/18 07:10
Compugen Q1 Revenue $2.2M, Cash Sufficient Until 2029
Reports Q1 revenue $2.2M vs. $2.3M last year. Compugen expects that its cash and cash-related balances will be sufficient to fund its operating plans into 2029. The company has no debt. "Q1 2026 reflects continued execution across all of our programs in line with our strategic priorities," said CEO Eran Ophir. "With enrollment progressing across all COM701 MAIA-ovarian trial sites, we remain on track for having the median progression-free survival at the interim analysis by Q1 2027, a key potential inflection point for COM701 as a maintenance therapy in a patient population with significant unmet medical need and no current standard of care. Our partner AstraZeneca continues to broadly advance rilvegostomig. In addition, we continue to advance the Gilead-partnered GS-0321 Phase 1 trial. Our solid financial position with cash runway expected into 2029, based on our current plans, enables us to advance our differentiated immuno-oncology pipeline and leverage our AI/ML powered computational discovery platform Unigen, to discover novel ways to activate the immune system against cancer. I remain encouraged by the progress of our fully owned programs, strengthened by validating partnerships with AstraZeneca and Gilead, which together offer approximately $1B in potential milestones plus royalties."

CGEN Monitor News

No data

No data

CGEN Earnings Analysis

No Data

No Data

People Also Watch